Navigation Links
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
Date:6/15/2009

Findings Published in Nature Medicine Suggest Broad Implications for the Treatment of Inflammatory and Autoimmune Disorders

SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Proteolix, Inc. announced that in an article published today in Nature Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical symptoms, including joint inflammation, and was more effective than etanercept in a model of aggressive arthritis.

These data were published in the June 14, 2009 online edition of Nature Medicine and will be published in the upcoming July 2009 print edition in an article titled: A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Progression of Experimental Arthritis. The authors of the article included members of the laboratory of Dr. Marcus Groettrup at the University of Constance (Konstanz, Germany) and researchers, led by Dr. Christopher Kirk, at Proteolix, Inc. (South San Francisco, CA), where the drug candidate was discovered and developed.

PR-957 is the first highly selective, small molecule inhibitor of the immunoproteasome. The proteasome is an intracellular complex present in most cells that mediates the degradation of intracellular proteins, including key components of pathways that contribute to cancer cell growth and immune signaling. It is a proven and val
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
2. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
3. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
4. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN JOSE, Calif. , June 29, 2015 ... its expert medical workstation lineup. The high-powered, multi-functional ... th generation Intel® Haswell Core ... processor. Both provide significant data processing and computing ... visual performance, making the unit well suited for ...
(Date:6/29/2015)... June 29, 2015  Sorrento Therapeutics, Inc. (NASDAQ: ... added to the Russell 2000® Small Cap, Russell 3000®, ... occurred at the close of trading on June 26, ... set of U.S. and global indexes. Sorrento is already ... About the Russell Indexes. Russell ...
(Date:6/29/2015)... , June 29, 2015 /PRNewswire/-- CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the presentation of interim ... evaluating the efficacy and safety of aldoxorubicin for the ... data will be presented on Wednesday, July 1, 2015 ... on Kaposi,s Sarcoma Herpesvirus (KSHV) and Related Agents in ...
Breaking Medicine Technology:Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes 2Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes 3CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 2CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 3CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 4CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 6
... GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... Human Immunodeficiency Virus (HIV) infections, announced today the completion ... its HIV/AIDS vaccine. The vaccine is being developed for ... be exposed to the virus. The trial, designated HVTN ...
... CIVCO Medical Solutions is pleased to announce the ... Advanced Robotics and Workflow Solutions. Ramirez will be ... Robotic Patient Positioning System and RFSuite RFID Tracking ... http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO ) "CIVCO is a leader ...
Cached Medicine Technology:GeoVax Phase 2a Clinical Trial Completes Enrollment 2GeoVax Phase 2a Clinical Trial Completes Enrollment 3GeoVax Phase 2a Clinical Trial Completes Enrollment 4CIVCO Appoints Andres Ramirez Sales Director of Advanced Robotics and Workflow Solutions 2
(Date:6/30/2015)... ... 2015 , ... Intellitec Solutions has announced they will be hosting two webinars ... enhanced changes and new procedures involved with updating the cloud version of Dynamics CRM, ... the new user interface and what it will mean for end users, critical items ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... is launching MEDFLOW 2.0 EHR, a SaaS electronic health records system from the ... perfect evolution in software, Medflow 2.0 delivers an intuitive state-of-the-art solution combining modern ...
(Date:6/30/2015)... ... ... Curly Hair Solutions™ is honoured to attend Cosmoprof North America in Las Vegas, ... all over the world. For the first time ever, Curly Hair Solutions™ will showcase ... focused entirely on meeting the needs of all curl types and provides ...
(Date:6/29/2015)... Topsfield, MA (PRWEB) , ... June 30, 2015 ... ... in Connecticut in early November at one of the industry’s premier thought leadership ... over 250 administrators, directors of nursing, rehabilitation managers and other management and corporate ...
(Date:6/29/2015)... , ... June 30, 2015 , ... With thousands of ... its involvement in a much-needed autism support center, planned at Utah Valley University, in ... formal approval for the center and the building in which it will be housed. ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions to Host Microsoft CRM 2015 Update Webinar 2Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 3Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3
... Research Institute shows that a bioptic telescope on one lens ... and lights may not prevent the wider view of the ... will be published in the May 2011 Archives of ... conditions than in earlier studies--the second eye can detect objects ...
... Researchers say they,ve pinpointed a number of factors that may ... Glaucoma is most often caused by an increase in ... U.S. National Eye Institute. The added pressure damages the optic ... that send signals from the eye to the brain. In ...
... (Garrison, NY) Medical involvement with torture is prohibited by ... is the right thing for doctors to do, argue ... Center Report comes as news of the trail ... to prisoners at Guantanamo Bay who were subject to ...
... An estimated five million Americans have Alzheimer,s disease. ... as the population ages reaching 13.5 million by 2050. ... Yeshiva University are among those investigating the origins and treatments ... (EAS) , which examines both normal brain aging and the ...
... News) -- Adults who undergo Roux-en-Y gastric bypass surgery ... that have the procedure may realize even greater heart ... In Roux-en-Y surgery, a very common gastric bypass procedure, ... and let food bypass part of the small intestine. ...
... to radiotherapy Men with prostate cancer ... prostate to immediately outside it are primarily treated ... half of these individuals. Strategies to enhance the ... incidence of disease recurrence are clearly needed. Shawn ...
Cached Medicine News:Health News:Single bioptic telescope for low vision driving may not obscure road view of second eye 2Health News:Single bioptic telescope for low vision driving may not obscure road view of second eye 3Health News:Researchers Outline Key Risk Factors for Glaucoma 2Health News:A grim dilemma: Treating the tortured prisoner 2Health News:A grim dilemma: Treating the tortured prisoner 3Health News:Einstein secures $11 million to continue research on brain aging and Alzheimer's disease 2Health News:Gastric Bypass May Help Prevent Heart Disease in Teens: Study 2Health News:JCI online early table of contents: May 9, 2011 2Health News:JCI online early table of contents: May 9, 2011 3Health News:JCI online early table of contents: May 9, 2011 4Health News:JCI online early table of contents: May 9, 2011 5Health News:JCI online early table of contents: May 9, 2011 6Health News:JCI online early table of contents: May 9, 2011 7Health News:JCI online early table of contents: May 9, 2011 8
... The TACIT Threaded Anchor ... used in craniofacial and ... easy, secure tissue reattachment ... suspension. The small size ...
ROC XS is a polyethylene implant used for soft tissue reattachment to bone. The umbrella-like deployment of this anchor provides increased fixation strength. This anchor is easy-to-insert using the R...
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
Medicine Products: